"Microecological new drug project" of Donghai pharmaceutical won the first prize of Qingdao technology invention

Qingdao Donghai Pharmaceutical Co., Ltd has experienced 8 years of painstaking research and development of a series of micro ecological new drug projects Recently, it has successfully realized industrialization and achieved great social benefits The project won the first prize of 2013 Municipal Technology Invention Award In the early 1990s, due to the abuse of antibiotics, even abuse in the treatment of chronic diarrhea, leading to the imbalance of intestinal flora, cold diarrhea, drinking diarrhea and other chronic diarrhea, irritable bowel syndrome, ulcerative colitis, colon cancer and other intestinal diseases, as well as children's eczema, jaundice and other pediatric diseases, and no effective treatment drugs In order to solve the current situation that there is no effective treatment drug for the above diseases, Qingdao Donghai pharmaceutical R & D team has obtained the first Clostridium caseinate and Bacillus coagulans strains with specific functions in China after 8 years of directional separation, created a strict high-density fermentation technology for high-yield spore rate of anaerobic bacteria, invented a preparation technology for room temperature storage and transportation, and solved the strict anaerobic bacteria Because of the technical bottleneck of low spore yield and low temperature storage and transportation of microecological drugs, four certificates of new microecological drugs have been obtained and industrialization has been realized Four national standards of microecological drugs have been formulated, breaking the technological monopoly in Japan This achievement has obtained 10 patents for invention of new microecological drugs, two of which have been granted by the United States, marking that the series of new microecological drugs developed by Qingdao Donghai pharmaceutical industry is ahead of the United States The research and development team also published five monographs and two scientific and educational films on Clostridium caseinate, Bacillus coagulans, intestinal flora and clinical, which not only improved the microecology and chemical theory, but also provided guidance for clinical scientific diagnosis and treatment After technical breakthrough, Qingdao Donghai pharmaceutical R & D team has developed a series of microecological new drugs with the advantages of repairing damaged intestinal mucosa, room temperature preservation, high safety (approved by the State Food and drug administration as "available for pregnant women and lactating women"), two-way treatment of stomach acid resistance, diarrhea and constipation, which has relieved the disease pain for millions of patients, including Academician Yuan Longping, and saved money Billions of dollars in medical expenses Because of its significant clinical effect, it has been highly recognized by clinical experts, and has been written into the expert consensus such as "recommendations for the diagnosis and treatment of intestinal flora disorders", "expert consensus on the application of microecological agents in pediatrics" as the recommended drug At present, a series of new microecological drugs have entered more than 2000 hospitals, including Shanghai Xinhua Hospital, West China Hospital and Tongji Hospital, with a total sales volume of more than 40 million boxes, an output value of more than 1.1 billion yuan, and a profit and tax of more than 130 million yuan.